Herceptin® (Trastuzumab): Questions and Answers
- What is Herceptin? How does it work?
- How is Herceptin currently used in the treatment of cancer?
- What are some of the common side effects of Herceptin?
- Can Herceptin cause any serious side effects?
- How did scientists study the effectiveness of Herceptin before it was approved by the FDA?
- Is Herceptin being studied to treat nonmetastatic breast cancer?
Herceptin is a monoclonal antibody. It belongs to a group of drugs made in the laboratory that are designed to attack specific cancer cells. Herceptin is given intravenously to treat some breast cancers. Genentech, Inc., located in South San Francisco, manufactures Herceptin.
Herceptin targets cancer cells that "overexpress," or make too much of, a protein called HER2 or erb B2, which is found on the surface of cancer cells. Herceptin slows or stops the growth of these cells. Herceptin is used only to treat cancers that overexpress the HER2 protein.
Approximately 25 to 30 percent of breast cancers overexpress HER2. These tumors tend to grow faster and are generally more likely to recur than tumors that do not overproduce HER2.
The amount of HER2 protein in the tumor is measured in the laboratory using a scale from 0 to 3+. The result helps the doctor determine whether a patient might benefit from treatment with Herceptin. Patients whose tumors are strongly positive for HER2 protein overexpression are more likely to benefit. There is no evidence of benefit in patients whose tumors do not overexpress HER2.
Herceptin is approved by the U.S. Food and Drug Administration for the treatment of metastatic breast cancer (breast cancer that has spread to other parts of the body). Herceptin can be given by itself or along with chemotherapy.
Researchers continue to study Herceptin in clinical trials. These studies can show whether new treatments are more or less effective than standard ones and how the side effects compare.
Side effects that most commonly occur during the first treatment with Herceptin include fever and/or chills. Other possible side effects include pain, weakness, nausea, vomiting, diarrhea, headaches, difficulty breathing, and rashes. These side effects generally become less severe after the first treatment with Herceptin.
Patients who receive Herceptin along with chemotherapy may experience side effects that are different from those of patients who take Herceptin by itself. Patients should discuss any concerns about the side effects of treatment with their doctor. The doctor may be able to make suggestions for managing side effects.
Herceptin can cause damage to the heart muscle that can lead to heart failure. Symptoms of heart failure include shortness of breath, difficulty breathing, a fast or irregular heartbeat, increased cough, and swelling of the feet or lower legs.
Herceptin can also affect the lungs, causing severe or life-threatening breathing problems that require immediate medical attention.
Herceptin may also cause allergic reactions that can be severe or life-threatening. These reactions can involve a drop in blood pressure, shortness of breath, rashes, and wheezing. These reactions may be more common in patients who already have breathing difficulties or lung disease.
Because of these potentially life-threatening side effects, patients are evaluated carefully for any heart or lung problems before starting treatment and are monitored closely during treatment. Patients who develop any problems during or after treatment should call the doctor immediately or go to the nearest emergency care facility.
The safety and effectiveness of Herceptin were studied in two clinical trials with women whose metastatic breast cancers produced excess amounts of HER–2. In one clinical trial, women received either Herceptin and chemotherapy or chemotherapy alone. The women who received Herceptin and chemotherapy had slower tumor growth, greater reduction in tumor size, and longer survival than the women who received chemotherapy alone. In another trial, women received Herceptin by itself. In 14 percent of these women, the tumor got smaller or disappeared. Scientists continue to study the safety and effectiveness of Herceptin in clinical trials.
Yes. The National Cancer Institute is sponsoring two large, multicenter phase III clinical trials of Herceptin as adjuvant therapy to treat node-positive breast cancer; this is breast cancer that has spread to the lymph nodes under the arm, but not to other parts of the body. These trials will take place in hospitals and cancer centers around the country. Adjuvant therapy is treatment given in addition to the primary therapy to kill any cancer cells that may have spread, even if the spread cannot be detected by radiologic or laboratory tests.
- The National Surgical Adjuvant Breast and Bowel Project is comparing chemotherapy alone to chemotherapy plus Herceptin for patients with
node-positive breast cancer. This trial will enroll 2,700 patients.
- The North Central Cancer Treatment Group is leading an Intergroup study to compare three different treatments in patients with node-positive breast cancer. This trial will enroll 3,000 patients.
Patients who are interested in receiving Herceptin as adjuvant therapy for breast cancer should consider participating in a clinical trial. For more information about these and other clinical trials, patients and doctors may call the Cancer Information Service or visit the NCI’s Web site at http://www.cancer.gov on the Internet.
Yes. Herceptin is also being studied in clinical trials for other types of cancer, including osteosarcoma and cancers of the lung, pancreas, salivary gland, colon, prostate, endometrium, and bladder. Some patients with these types of cancer have tumors that overexpress the HER–2 protein. These patients will be possible candidates for clinical trials with Herceptin.
Researchers are exploring the use of Herceptin by itself and in combination with anticancer drugs. They are also investigating the use of Herceptin with other types of cancer treatment.